Scarica l'app Stockscreener
0.8709
3.50%
-0.0316
Dopo l'orario di chiusura:
.88
0.0091
+1.04%
Precedente Chiudi:
$0.9025
Aprire:
$0.93
Volume 24 ore:
160.57K
Relative Volume:
0.39
Capitalizzazione di mercato:
$47.93M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.4893
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
-10.22%
1M Prestazione:
-28.61%
6M Prestazione:
-83.75%
1 anno Prestazione:
-76.96%
Intervallo 1D:
$0.8685
$0.93
Intervallo di 1 settimana:
$0.868
$0.9908
Portata 52W:
$0.7966
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.8709 | 47.93M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Prelude Therapeutics (PRLD) Stock Price, News & Analysis - MarketBeat
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World
Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com
Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MSN
D2 Capital Advisors secures $23.5m for Residence Inn in Wilmington - Hotel Management Network
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Purchased by Barclays PLC - Defense World
Adenoid Cystic Carcinoma Market reached US$ 224.3 million - openPR
US Penny Stocks To Watch In January 2025 - Simply Wall St
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
A Look At The Behavior Of Prelude Therapeutics Inc (PRLD) Stock - Stocks Register
Geode Capital Management LLC Grows Stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stake Lifted by Barclays PLC - Defense World
State Street Corp Raises Stock Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock - Investing.com India
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock By Investing.com - Investing.com UK
Prelude Therapeutics CEO Vaddi Krishna acquires $12,000 in stock - Investing.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares - MarketBeat
Insider Buying: Andrew Combs Acquires 63,075 Shares of Prelude T - GuruFocus.com
Andrew Combs Purchases 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat
XTX Topco Ltd Makes New $100,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics - Yahoo Finance UK
Insider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Purchases 100,000 Shares of Stock - MarketBeat
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Purchases $22,750.00 in Stock - MarketBeat
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics’ interim CFO Bryant Lim buys $22,637 in stock By Investing.com - Investing.com Nigeria
Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com India
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo
Prelude Therapeutics presents first interim data from trial of PRT2527 - Yahoo Finance
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Position Increased by Walleye Capital LLC - Defense World
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 - The Bakersfield Californian
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - Yahoo Finance
Sirus Therapeutics announces positive signals from Phase I siRNA trial - Yahoo Finance
PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges - Investing.com Nigeria
Foghorn Therapeutics patents new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online
November 2024's Top Picks: Penny Stocks On US Exchanges - Simply Wall St
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD) - Yahoo Finance
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - Yahoo Finance
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):